# A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

> **NCT03539601** · PHASE4 · TERMINATED · sponsor: **Pfizer** · enrollment: 237 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Crisaborole ointment, 2%
- **DRUG:** Hydrocortisone butyrate cream, 0.1%
- **DRUG:** Pimecrolimus cream, 1%
- **DRUG:** Crisaborole Vehicle

## Key facts

- **NCT ID:** NCT03539601
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-27
- **Primary completion:** 2020-12-11
- **Final completion:** 2020-12-11
- **Target enrollment:** 237 (ACTUAL)
- **Why stopped:** This decision was made for business reasons only and is not related to any safety concerns regarding crisaborole.
- **Last updated:** 2022-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03539601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03539601, "A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03539601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*